NASD · Healthcare · Diagnostics & Research · USA
Veracyte Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.
Veracyte is a global diagnostics company offering molecular tests to help clinicians make cancer diagnosis and treatment decisions. In the United States, it provides laboratory-developed tests through CLIA-certified labs for prostate, thyroid, breast, and bladder cancers. Outside the United States, it distributes in vitro diagnostic tests to hospitals and laboratories.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Veracyte Inc stock.
Undervalued: intrinsic value $30.97 per share, market price $24.23, margin of safety 21.8% (as of 2026-11-17).
Discounting its cash flows at 13.6% (average of 3 methods) values the shares at $30.97; the price of $24.23 is 22% below that value, and 64% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
VCYT is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 13.6% (average of 3 methods) values the shares at $30.97; the price of $24.23 is 22% below that value, and 64% of that value comes from beyond year five.
$30.97 per share (as of the 2026-11-17 close), against a market price of $24.23. That is a margin of safety of 21.8%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.